RBM20 and familial dilated cardiomyopathy: Both ABE and PE were used to efficiently correct the DCM-risk dominant mutations R634Q and R636S in RBM20 in human iPSCs, as well as the mutation R636Q in the mouse model Rbm20R636Q, which recapitulates human DCM phenotypes [114].